A “life-changing” device being developed in Clonmel needs to be made available to patients in Ireland. That was the fundamental take-home from Boston Scientific Clonmel’s annual Everybody Makes an ...
US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial fibrillation (AF) as the company looks to ...
Credit: Shutterstock / Good dreams – Studio US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback